BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Amgen  Europe  B.V.  submitted  on  17  December  1999  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Aranesp, 
in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the  Annex  to 
Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Prof. R. Bass 
Co-Rapporteur:  Dr. D. Brasseur 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 21 January 2000. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 3 April 2000. 
The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 
4 April 2000. 
The  CPMP  at  its  meeting  of  11-13  April  2000  decided  that  there  was  a  need  for  a  GMP 
inspection  of  the  active  substance  manufacturing  site.  An  inspection  of  three  contract 
laboratories (Rockville, MD; Malvern, PA; Camden, New Jersey) was also requested. 
During the meeting on 23-24 May 2000 the CPMP agreed on the consolidated list of questions 
to be sent to the company. The final consolidated list of questions was sent to the company on 
25 May 2000. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on 
12 October 2000. 
The  company  submitted  on  22  November  2000  Certificates  of  suitability  from  the  European 
Pharmacopoeia for two of the suppliers of the Foetal bovine serum used during the manufacture 
of Aranesp.  
The Rapporteur circulated the joint response assessment report on the company’s responses to 
the list of questions to all CPMP Members on 24 November 2000. 
During  the  CPMP  meeting  on  12-14  December  2000,  the  CPMP  issued  a  list  of  outstanding 
questions to be addressed by the applicant during an oral explanation. 
The applicant submitted to the EMEA and the CPMP members on 8 January 2001 responses to 
the outstanding quality questions from the response assessment report. 
The Rapporteur circulated an Amendment to the Response Assessment Report on Part II to all 
CPMP members on 10 January 2001. 
During the BWP meeting of 16-17 January 2001, all outstanding quality issues were discussed. 
The BWP prepared a Recommendation to the CPMP. 
1/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
The  applicant  submitted  to  the  EMEA  and  the  CPMP  members  on  10  and  16  January  2001 
background documentation for the oral explanation. 
The  Rapporteur  and  Co-Rapporteur  circulated  an  Amendment  to  the  Joint  Assessment  Report 
on 19 January 2001. 
During the CPMP meeting of 23-25 January 2001, the outstanding issues were addressed by the 
applicant during an oral explanation before the CPMP.  
During the meeting on 27 February – 1 March 2001, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting 
Marketing Authorisations to Aranesp on 1 March 2001. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 8 June 2001. 
2/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
